Use of nude mouse xenograft models in prostate cancer research

Prostate

Volumn 43, Issue 4, 2000, Pages 263-271

  Van Weerden, Wytske M ^a   Romijn, Johannes C ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Human prostate cancer; Immunodeficient mice; Xenograft models

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER RESEARCH; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL RESEARCH; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; XENOGRAFT;

ANIMALS; HUMANS; MALE; MICE; MICE, NUDE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034212783     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000601)43:4<263::AID-PROS5>3.0.CO;2-I     Document Type: Article

References (50)

1. Newling DWW. The geography of prostate cancer and its treatment in Europe. Cancer Surv 1995;23:289-296.
2. Paterson AHG. Bone metastases in breast cancer, prostate cancer, and myeloma. Bone [Suppl] 1987;8:17-22.
3. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem [Suppl] 1992;16:89-98.
4. Bosland MC, Chung LWK, Greenberg NM, Ho S-M, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research: a minireview. Urol Oncol 1997;2:99-128.
5. Isaacson JH, Cattanach BM. Report. Mouse News Lett 1962;27: 31.
6. Pandelouris EM. Absence of thymus in a mouse mutant. Nature 1968;217:370-371.
7. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumor to "nude" mice. Acta Pathol Microbiol Scand 1969;77:758-760.
8. Povlsen CO, Rygaard J. Heterotransplantation of human adenocarcinomas of the colon and rectum to the mouse mutant nude. A study of nine consecutive transplantations. Acta Pathol Microbiol Scand 1971;79:159-169.
9. Hoehn W, Schröder FH, Riemann JF, Joebsis AC, Hermanek P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1980;1: 95-104.
10. Hoehn W, Wagner M, Riemann JF, Hermanek P, Williams E, Walther R, Schrueffer R. Prostatic adenocarcinoma PC-EW, a new human tumor line transplantable in nude mice. Prostate 1984;5:445-452.
11. van Weerden WM, van Steenbrugge GJ, van Kreuningen A, Moerings EPCM, de Jong FH, Schröder FH. Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol 1990; 37:903-907.
12. van Weerden WM, de Ridder CMA, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996;149:1055-1062.
13. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR. Basement membrane complexes with biological activity. Biochemistry 1986;25:312-318.
14. Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney TM, Jicha DL, Yannelli JR, Martin GR, Kleinman HK. Enhanced tumor growth of both primary and established murine tumor cells in athymic nude mice after coinjection with Matrigel. J Natl Cancer Inst 1991;83:769-774.
15. Fong CJ, Sherwood ER, Sutkowski DM, Abu-Jawdeh GM, Yokoo H, Bauer KD, Kozlowski JM, Lee C. Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Prostate 1991; 19:221-235.
16. Freeman MR, Bagli DJ, Lamb CC, Guthrie PD, Uchida T, Slavin RE, Chung LW. Culture of a prostatic cell line in basement membrane gels results in an enhancement of malignant properties and constitutive alterations in gene expression. J Cell Physiol 1994;158:325-336.
17. Festing MFW. International index of laboratory animals. Leicester: University of Leicester; 1968.
18. Wagner B, Otto U, Becker H, Schröder S, Klosterhalfen H. Transplantation of human normal prostate or BPH tissue into NMRI nu/nu mice: reliability of an experimental model. Urol Res 1989;17:340.
19. van Weerden WM, Romijn JC, de Ridder CMA, van der Kwast TH, van Steenbrugge GJ, Schröder FH. Frequent occurrence of spontaneous tumors in NMRI athymic nude mice. Contrib Oncol 1996;51:41-44.
20. Johnston JO, Wright CL, Wallace CD, Thompson FY, Montgomery LR, Loudy DE, Adler R, Sprinkle-Cavallo J. Occurrence of androgen-independent murine stromal tumors following transplantation of androgen-dependent human prostatic (PC-82) xenografts in nude mice. In: 75th Annual Meeting of the Endocrine Society, Las Vegas 1993. p 299B [abstract].
21. van Weerden WM, van Kreuningen A, Elissen NMJ, Vermeij M, de Jong FH, van Steenbrugge GJ, Schröder FH. Castration-induced changes in morphology, androgen levels and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate 1993;23:149-164.
22. Noordzij MA, van Weerden WM, de Ridder CMA, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996;149:859-871.
23. Jongsma J, Oomen MH, Noordzij MA, van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 1999; 154:543-551.
24. Jongsma J, Oomen MH, Noordzij MA, van Weerden WM, Martens GJM, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Androgen deprivation of the PC-310 human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000;60:741-748.
25. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 1991;51:3814-3817.
26. Wainstein MA, He F, Robinson D, Kung H-J, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A, Pretlow TG. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-6052.
27. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains in vivo and in soft agar. Cancer Res 1996; 56:3042-3046.
28. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang D-Y, Sar M, Gumerlock PH, de Vere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-459.
29. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 1999;17:361-371.
30. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3: 402-408.
31. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Saywers CL. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59:5030-5036.
32. Van Steenbrugge GJ, Groen M, Romijn JC, Schröder FH. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J Urol 1984;131:812-817.
33. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-1048.
34. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu M, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
35. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
36. Cleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51: 3753-3761.
37. Lim DJ, Liu X-L, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993;22:109-118.
38. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-1936.
39. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3: 2493-2500.
40. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA Pca 2a. J Urol 1999;162:2192-2199.
41. Jacobs SC. Spread of cancer to bone. Urology 1983;21:337-344.
42. Stephenson RA, Dinney CN, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84: 951-957.
43. Fu X, Herrera H, Hoffman RM. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histological intact tissue. Int J Cancer 1992;52:987-990.
44. Rembrink K, Romijn JC, Ruizeveld de Winter JA, Schröder FH. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997;31:168-174.
45. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54:2577-2581.
46. Nemeth JA, Harb JF, Barroso U, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-1993.
47. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65:85-89.
48. Chang GTG, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO. Differentially expressed genes in androgen-dependent and androgen-independent prostate carcinomas. Cancer Res 1997;57:4075-4081.
49. Chang GTG, Tapsi N, Steenbeek M, Blok LJ, van Weerden WM, van Alewijk DCJG, Eussen BHJ, van Steenbrugge GJ, Brinkmann AO. Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression. Int J Cancer 1999;83:506-511.
50. Bubendorf L, Kolmer M, Kononen J, Mousses S, Chen Y, Kallioniemi O-P. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999;20:1758-1764.